Amyris has completed a Chapter 11 restructuring and divested its consumer brands

May 2024 — Amyris, Inc. has successfully completed a Chapter 11 restructuring and divested its consumer-facing brands.

Amyris is a leading synthetic biology and consumer products company headquartered in Emeryville, California. Through proprietary technology, cell programming and the fermentation of sugar and yeast, Amyris successfully developed one of the largest global libraries of clean, sustainable ingredients and a portfolio of beauty and personal care brands. It generated revenue through two main segments: consumer and technology access. The consumer segment comprised seven operating beauty and wellness brands, while the technology access segment supplied high-performing, sustainable molecules as ingredients to industry leaders across multiple end markets.

Our role in the transaction

Oaklins Intrepid, based in Los Angeles, acted as the exclusive financial advisor to Amyris in the sale of its consumer brands portfolio through a Chapter 11 section 363 process. The team conducted a comprehensive sale process and successfully closed the sale of all seven consumer brands, including Biossance, JVN, Rose Inc., MenoLabs, Stripes, Pipette and 4U by Tia. In support of the Plan of Reorganization, Oaklins Intrepid also managed the sale process of technology access assets and provided expert testimony for the Plan. Following the consumer brands sales and completion of the required milestones, Amyris emerged from Chapter 11 in February 2024 with a clear focus in the future of its technology and R&D assets.